Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP)

S Culine1 P Kerbrat2 A Kramar1 C Théodore3 C Chevreau4 L Geoffrois5 NB Bui6 J Pény7 A Caty8 R Delva9 P Biron10 K Fizazi3 J Bouzy3 and JP Droz10

首页> 外文期刊>Annals of Oncology >Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP)

【24h】

Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP)

机译：完善针对高风险转移性非精原细胞性生殖细胞肿瘤的最佳化疗方案：法国癌症中心联合会泌尿生殖系统小组（GETUG T93BP）的一项随机试验

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: High cure rates are expected in good-risk metastatic nonseminomatous germ-cell tumor (NSGCT) patients with bleomycin, etoposide and cisplatin.

机译：背景：患有博来霉素，依托泊苷和顺铂的高危转移性非精原细胞性生殖细胞肿瘤（NSGCT）患者有望获得高治愈率。

著录项

来源
《Annals of Oncology》 |2007年第5期|917-924|共8页
作者
S Culine1 P Kerbrat2 A Kramar1 C Théodore3 C Chevreau4 L Geoffrois5 NB Bui6 J Pény7 A Caty8 R Delva9 P Biron10 K Fizazi3 J Bouzy3 and JP Droz10;
展开▼
作者单位

CRLC Val d'Aurelle Montpellier;

Centre Eugène Marquis Rennes;

Institut Gustave Roussy Villejuif;

Institut Claudius Régaud Toulouse;

Centre Alexis Vautrin Nancy;

Institut Bergonié Bordeaux;

Centre François Baclesse Caen;

Centre Oscar Lambret Lille;

Centre Eugène Papin Angers;

Centre Léon Bérard Lyon France;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献

1. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). [J] . Culine S, Kerbrat P, Kramar A, Annals of oncology: official journal of the European Society for Medical Oncology . 2007,第5期

机译：完善针对高风险转移性非精原细胞生殖细胞肿瘤的最佳化疗方案：法国癌症中心联合会泌尿生殖系统小组（GETUG T93BP）的一项随机试验。
2. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial. [J] . Flechon A, Pouessel D, Ferlay C, Annals of oncology: official journal of the European Society for Medical Oncology . 2011,第11期

机译：伴或不伴神经内分泌分化的间变性进展性去势抵抗性前列腺癌（mCRPC）患者中卡铂和依托泊苷的II期研究：法国生殖泌尿肿瘤小组（GETUG）P01试验的结果。
3. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostaten cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01n trial [J] . S. Culine Annals of Oncology . 2011,第11期

机译：伴或不伴神经内分泌分化的间变性进展性去势抵抗性前列腺癌（mCRPC）患者中卡铂和依托泊苷的II期研究：法国生殖泌尿肿瘤小组（GETUG）P01n试验的结果
4. Design of a randomized controlled phase III study of dose dense methotrexate vinblastine doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial [O] . Christian Pfister, Valentin Harter, Yves Allory, 2020

机译：剂量密集的甲氨蝶呤长春碱阿霉素和顺铂（dd-MVAC）或吉西他滨和顺铂（GC）作为围手术期化疗的局部晚期膀胱癌患者的随机对照III期研究设计。法国GETUG / AFU V05 VESPER试用版
5. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial [O] . Karim Fizazi, Lance Pagliaro, Agnes Laplanche, 2014

机译：基于肿瘤标志物的个性化化疗在差的预后细胞肿瘤差（Getug 13）：3，多期，随机试验

Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP)

摘要

著录项

相似文献

相关主题

期刊订阅